Metabolically Healthy Obesity
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hyperplasia, referring to an increase in the number of adipocytes, is associated with an increase in subcutaneous fat volume and protective signals, and is associated with MHO (50).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, hypertrophic adipocytes, in which existing adipocytes enlarge, is associated with increased dysfunction and MUHO (50), which contributes to IR and subsequent T2D (52, 53).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Self-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Years of Life Lost Due to Obesity
Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. O., & Allison, D. B. (2003) · JAMA · doi:10.1001/jama.289.2.187 · Cited by 2,495
Body-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
General and abdominal adiposity and risk of death in Europe
Pischon, T., Boeing, H., Hoffmann, K., Bergmann, M., Schulze, M. B., Overvad, K., van der Schouw, Y. T., Spencer, E., Moons, K. G. M., Tjønneland, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801891 · Cited by 2,155
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30084-1 · Cited by 1,603
The Degree of Masculine Differentiation of Obesities
VAGUE, J. (1956) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/4.1.20 · Cited by 1,410
Adipogenesis and metabolic health
Ghaben, A. L., & Scherer, P. E. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0093-z · Cited by 1,395
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310
Body Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease
Meigs, J. B., Wilson, P. W. F., Fox, C. S., Vasan, R. S., Nathan, D. M., Sullivan, L. M., & D’Agostino, R. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0594 · Cited by 1,062
Identification and characterization of metabolically benign obesity in humans
Stefan, N. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1609 · Cited by 1,049
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036
Kramer, C. K., Zinman, B., & Retnakaran, R. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-11-201312030-00008 · Cited by 961
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885
Neeland, I. J., Poirier, P., & Després, J.-P. (2018) · Circulation · doi:10.1161/circulationaha.117.029617 · Cited by 881
Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications
Stefan, N., Häring, H.-U., Hu, F. B., & Schulze, M. B. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70062-7 · Cited by 857
Klöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M. R., Kern, M., Stumvoll, M., & Blüher, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2009 · Cited by 856
Self-citationle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Self-citationO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates
Mullican, S. E., Lin-Schmidt, X., Chin, C.-N., Chavez, J. A., Furman, J. L., Armstrong, A. A., Beck, S. C., South, V. J., Dinh, T. Q., Cash-Mason, T. D., et al. (2017) · Nature Medicine · doi:10.1038/nm.4392 · Cited by 774
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis.
Crewe, C., An, Y. A., & Scherer, P. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88883 · Cited by 732
Kivimäki, M., Kuosma, E., Ferrie, J. E., Luukkonen, R., Nyberg, S. T., Alfredsson, L., Batty, G. D., Brunner, E. J., Fransson, E., Goldberg, M., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30074-9 · Cited by 691
A proposed clinical staging system for obesity
Sharma, A. M., & Kushner, R. F. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.2 · Cited by 687
van Vliet‐Ostaptchouk, J. V., Nuotio, M.-L., Slagter, S. N., Doiron, D., Fischer, K., Foco, L., Gaye, A., Gögele, M., Heier, M., Hiekkalinna, T., et al. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-9 · Cited by 686
Adipose Tissue Dysfunction in Obesity
Blüher, M. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1192044 · Cited by 662
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals
Blüher, M. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283346ccc · Cited by 632
Self-citationvan Vliet‐Ostaptchouk, J. V., Nuotio, M.-L., Slagter, S. N., Doiron, D., Fischer, K., Foco, L., Gaye, A., Gögele, M., Heier, M., Hiekkalinna, T., et al. (2014) · NORA - Norwegian Open Research Archives · Cited by 620
Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W.-W., Bauskin, A. R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1677 · Cited by 612
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans
Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575 · cited 3×
“In a large BMI-stratified cohort, Stefan et al (20, 23) linked high liver fat content and predominantly abdominal (including visceral) adiposity to MUO, whereas greater insulin sensitivity, better insulin secretion, cardiorespiratory fitness, and lower body subcutaneous fat mass were associated with an MHO phenotype.”
BackgroundCaleyachetty, R., Thomas, G. N., Toulis, K. A., Mohammed, N., Gokhale, K. M., Balachandran, K., & Nirantharakumar, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.763 · Cited by 574 · cited 8×
“5 million men and women for which validated electronic health records were available in the context of The Health Improvement Network (THIN) database is most likely overestimated, because the definition of MHO did not consider blood glucose, blood pressure, or lipid parameter cutoffs (43, 44).”
BackgroundMethodResultInfluentialLee, D.-C., Sui, X., Artero, E. G., Lee, I.-M., Church, T. S., McAuley, P. A., Stanford, F. C., Kohl, H. W., & Blair, S. N. (2011) · Circulation · doi:10.1161/circulationaha.111.038422 · Cited by 572
Wang, G.-X., Zhao, X.-Y., Meng, Z.-X., Kern, M., Dietrich, A., Chen, Z., Cozacov, Z., Zhou, D., Okunade, A. L., Su, X., et al. (2014) · Nature Medicine · doi:10.1038/nm.3713 · Cited by 505
Self-citationProopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L. L., Mai, K., Blume-Peytavi, U., Grüters, A., & Krude, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512693 · Cited by 485
Diabetes and Cardiovascular Disease Outcomes in the Metabolically Healthy Obese Phenotype
Appleton, S. L., Seaborn, C. J., Visvanathan, R., Hill, C. L., Gill, T. K., Taylor, A. W., Adams, R. J., & on behalf of the North West Adelaide Health Study Team (2013) · Diabetes Care · doi:10.2337/dc12-1971 · Cited by 478
Kusminski, C. M., Holland, W. L., Sun, K., Park, J., Spurgin, S. B., Lin, Y., Askew, G. R., Simcox, J. A., McClain, D. A., Li, C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2899 · Cited by 470
Ortega, F. B., Lee, D.-C., Katzmarzyk, P. T., Ruiz, J. R., Sui, X., Church, T. S., & Blair, S. N. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs174 · Cited by 468
Healthy Weight and Obesity Prevention
Lavie, C. J., Laddu, D., Arena, R., Ortega, F. B., Alpert, M. A., & Kushner, R. F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1037 · Cited by 458
Eckel, N., Li, Y., Kuxhaus, O., Stefan, N., Hu, F. B., & Schulze, M. B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30137-2 · Cited by 457
Bell, J. A., Kivimaki, M., & Hamer, M. (2014) · Obesity Reviews · doi:10.1111/obr.12157 · Cited by 455
Are there persons who are obese, but metabolically healthy?
Sims, E. A. H. (2001) · Metabolism · doi:10.1053/meta.2001.27213 · Cited by 453
Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk
Mongraw-Chaffin, M., Foster, M. C., Anderson, C. A. M., Burke, G. L., Haq, N., Kalyani, R. R., Ouyang, P., Sibley, C. T., Tracy, R., Woodward, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.055 · Cited by 431
Adipose tissue dysfunction contributes to obesity related metabolic diseases
Blüher, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.02.005 · Cited by 408
Self-citationMetabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis.
Eckel, N., Meidtner, K., Kalle-Uhlmann, T., Stefan, N., & Schulze, M. B. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487315623884 · Cited by 405
Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study
Nyberg, S. T., Batty, G. D., Pentti, J., Virtanen, M., Alfredsson, L., Fransson, E. I., Goldberg, M., Heikkilä, K., Jokela, M., Knutsson, A., et al. (2018) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30139-7 · Cited by 392
Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
Rey‐López, J. P., de Rezende, L. F., Pastor‐Valero, M., & Tess, B. H. (2014) · Obesity Reviews · doi:10.1111/obr.12198 · Cited by 310
Metabolically healthy obesity: the low-hanging fruit in obesity treatment?
Stefan, N., Häring, H.-U., & Schulze, M. B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30292-9 · Cited by 309
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Adipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Self-citationFan, J., Song, Y., Chen, Y., Hui, R., & Zhang, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.230 · Cited by 266
Metabolically Healthy but Obese, a Matter of Time? Findings From the Prospective Pizarra Study
Soriguer, F., Gutiérrez-Repiso, C., Rubio-Martín, E., García-Fuentes, E., Almaraz, M. C., Colomo, N., Esteva de Antonio, I., de Adana, M. S. R., Chaves, F. J., Morcillo, S., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4253 · Cited by 251
Metabolically healthy obesity: different prevalences using different criteria
Velho, S., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2010.114 · Cited by 249
Chen, G.-C., Arthur, R., Iyengar, N. M., Kamensky, V., Xue, X., Wassertheil-Smoller, S., Allison, M. A., Shadyab, A. H., Wild, R. A., Sun, Y., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz391 · Cited by 240
Risk of Myocardial Infarction and Heart Failure Among Metabolically Healthy But Obese Individuals
Mørkedal, B., Vatten, L. J., Romundstad, P. R., Laugsand, L. E., & Janszky, I. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.035 · Cited by 235
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Adipose Dipeptidyl Peptidase-4 and Obesity
Sell, H., Blüher, M., Klöting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W. T., Dietrich, A., Fielding, B. A., Arner, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0496 · Cited by 218
Self-citationZheng, R., Zhou, D., & Zhu, Y. (2016) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2015-206948 · Cited by 203
McLaughlin, T. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.7.642 · Cited by 201
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Determinants of diabetes remission and glycemic control after bariatric surgery
Panunzi, S., Carlsson, L., De Gaetano, A., Peltonen, M., Rice, T., Sjöström, L., Mingrone, G., & Dixon, J. B. (2016) · Diabetes Care · doi:10.2337/dc15-0575 · Cited by 198
What is a disease?: Disease, disability and their definitions
Scully, J. L. (2004) · The EMBO Reports · doi:10.1038/sj.embor.7400195 · Cited by 195
Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D Survey
Pajunen, P., Kotronen, A., Korpi-Hyövälti, E., Keinanen-Kiukaanniemi, S. M., Oksa, H. H., NISKANEN, L. K., Saaristo, T., Saltevo, J. T., Sundvall, J., Vanhala, M. J., et al. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-754 · Cited by 182
MECHANISMS IN ENDOCRINOLOGY: Are metabolically healthy obese individuals really healthy?
Blüher, M. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0540 · Cited by 177
Self-citationPredictors of Metabolically Healthy Obesity in Children
Prince, R. L., Kuk, J. L., Ambler, K. A., Dhaliwal, J., & Ball, G. D. C. (2014) · Diabetes Care · doi:10.2337/dc13-1697 · Cited by 177
Lin, H., Zhang, L., Zheng, R., & Zheng, Y. (2017) · Medicine · doi:10.1097/md.0000000000008838 · Cited by 172
Tan, C. Y., & Vidal-Puig, A. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360935 · Cited by 169
Brauer, P., Gorber, S. C., Shaw, E., Singh, H., Bell, N., Shane, A. R. E., Jaramillo, A., Tonelli, M., & Canadian Task Force on Preventive Health Care (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.140887 · Cited by 169
Metabolically healthy but obese women: effect of an energy-restricted diet
Karelis, A. D., Messier, V., Brochu, M., & Rabasa-Lhoret, R. (2008) · Diabetologia · doi:10.1007/s00125-008-1038-4 · Cited by 165
All-Cause Mortality Risk of Metabolically Healthy Obese Individuals in NHANES III
Durward, C. M., Hartman, T. J., & Nickols‐Richardson, S. M. (2012) · Journal of Obesity · doi:10.1155/2012/460321 · Cited by 161
Metabolically healthy obesity: what–s in a name?
Magkos, F. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz133 · Cited by 160
Ortega, F. B., Cadenas‐Sánchez, C., Migueles, J. H., Labayen, I., Ruiz, J. R., Sui, X., Blair, S. N., Martínez‐Vizcaíno, V., & Lavie, C. J. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.008 · Cited by 158
Effects of a lifestyle intervention in metabolically benign and malign obesity
Kantartzis, K., Machann, J., Schick, F., Rittig, K., Machicao, F. E., Fritsche, A., Häring, H., & Stefan, N. (2010) · Diabetologia · doi:10.1007/s00125-010-2006-3 · Cited by 155
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · cited 1×
“Moreover, based on the metabolic benefits demonstrated for GLP-1/glucagon and GLP-1/GIP coagonists (“twincretins”), triagonists targeting all 3 incretin receptors have been systematically developed with even stronger efficacy compared to twincretins on weight loss and obesity-related traits, such as reducing liver fat…”
BackgroundNon-alcoholic fatty liver disease and risk of type 2 diabetes
Lallukka, S., & Yki‐Järvinen, H. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.006 · Cited by 146
Effects of Weight Loss Among Metabolically Healthy Obese Men and Women
Janiszewski, P. M., & Ross, R. (2010) · Diabetes Care · doi:10.2337/dc10-0547 · Cited by 123
Müller, M. J., & Geisler, C. (2017) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2017.155 · Cited by 118
The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria
Liu, C., Wang, C., Guan, S., Liu, H., Wu, X., Zhang, Z., Gu, X., Zhang, Y., Zhao, Y., Tse, L. A., et al. (2019) · Obesity Facts · doi:10.1159/000495852 · Cited by 109
Lotta, L. A., Abbasi, A., Sharp, S. J., Sahlqvist, A., Waterworth, D. M., Brosnan, J. M., Scott, R. A., Langenberg, C., & Wareham, N. J. (2015) · Diabetes Care · doi:10.2337/dc15-1218 · Cited by 103
Liu, J., Musani, S. K., Bidulescu, A., Carr, J. J., Wilson, J. G., Taylor, H. A., & Fox, C. S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.07.042 · Cited by 95
Khera, R., Pandey, A., Chandar, A. K., Murad, M. H., Prokop, L. J., Neeland, I. J., Berry, J. D., Camilleri, M., & Singh, S. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.024 · Cited by 90
The Impact of Obesity in Heart Failure
Carbone, S., Lavie, C. J., Elagizi, A., Arena, R. A., & Ventura, H. O. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.008 · Cited by 86
Prevalence and Clinical Profile of Metabolic Obesity and Phenotypic Obesity in Asian Indians
Geetha, L., Deepa, M., Anjana, R. M., & Mohan, V. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500235 · Cited by 84
Relationship Between 12 Adipocytokines and Distinct Components of the Metabolic Syndrome
Ebert, T., Gebhardt, C., Scholz, M. R., Wohland, T., Schleinitz, D., Faßhauer, M., Blüher, M., Stümvoll, M., Kovacs, P. L., & Tönjes, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02085 · Cited by 74
Self-citationClemmensen, C., Jall, S., Kleinert, M., Quarta, C., Gruber, T., Reber, J., Sachs, S., Fischer, K., Feuchtinger, A., Karlas, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06769-y · Cited by 60
Sesti, G., Folli, F. B., Perego, L., Hribal, M. L., & Pontiroli, A. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017737 · Cited by 55
Pérez, J. A. C., Quesada, C. F., Marco, M. D. V. G., González, I. A., Benavides, F. J. C., Ponce, J., de Pablos-Velasco, P. L., & Marchena‐Gómez, J. (2018) · Obesity Surgery · doi:10.1007/s11695-017-3107-6 · Cited by 55
Kuk, J. L., Rotondi, M. A., Sui, X., Blair, S. N., & Ardern, C. I. (2018) · Clinical Obesity · doi:10.1111/cob.12263 · Cited by 53
Vallgårda, S., Nielsen, M. E. J., Hansen, A. K., Cathaoir, K. Ó., Hartlev, M., Holm, L., Christensen, B., Jensen, J. D., Sørensen, T. I. A., & Sandøe, P. (2017) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2017.103 · Cited by 48
Ruiz, J. R., Ortega, F. B., & Labayen, I. (2013) · Annals of Nutrition and Metabolism · doi:10.1159/000345026 · Cited by 44
Kabat, G. C., Wu, W., Bea, J. W., Chen, C., Qi, L., Stefanick, M. L., Chlebowski, R. T., Lane, D. S., Wactawski‐Wende, J., Wassertheil-Smoller, S. W., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.179 · Cited by 44
Gummesson, A., Strömberg, U., Schmidt, C., Kullberg, J., Angerås, O., Lindgren, S. C., Hjelmgren, O., Torén, K., Rosengren, A., Fagerberg, B., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202666 · Cited by 40
Is the Metabolically Healthy Obesity Phenotype an Irrelevant Artifact for Public Health?
Rey-López, J. P., Rezende, L. F. M., de Sá, T. H., & Stamatakis, E. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv177 · Cited by 39
The Metabolically Healthy But Obese Phenotype in African Americans
Cherqaoui, R., Kassim, T. A., Kwagyan, J., Freeman, C., Nunlee‐Bland, G., Ketete, M., Xu, S., & Randall, O. S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00565.x · Cited by 38
Palau‐Rodriguez, M., Garcia‐Aloy, M., Miñarro, A., Bernal-López, M. R., Brunius, C. F., Gómez‐Huelgas, R., Landberg, R., Tinahones, F. J., & Andrés‐Lacueva, C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.01.018 · Cited by 38
Moussa, O., Arhi, C., Ziprin, P., Darzi, A. W., Khan, O. A., & Purkayastha, S. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0096-z · Cited by 37
Pelascini, É., Disse, E., Pasquer, A., Poncet, G., Gouillat, C., & Robert, M. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.04.024 · Cited by 32
Börnhorst, C., Russo, P., Veidebaum, T., Tornaritis, M. J., Molnár, D., Lissner, L., Mårild, S., Henauw, S. D., Moreno, L. A., Intemann, T., et al. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz097 · Cited by 30
Dangers and Long-Term Outcomes in Metabolically Healthy Obesity
DEEDWANIA, P. C., & Lavie, C. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.057 · Cited by 27
Yoon, D. Y., Lee, Y. A., Lee, J., Kim, J. H., Shin, C. H., & Yang, S. W. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.11.1840 · Cited by 25
A metabolically healthy obese phenotype in hispanic participants in the IRAS family study
Samaropoulos, X. F., Hairston, K. G., Anderson, A., Haffner, S. M., Lorenzo, C., Montez, M. G., Norris, J. M., Scherzinger, A. L., Chen, Y. I., & Wagenknecht, L. E. (2013) · Obesity · doi:10.1002/oby.20326 · Cited by 20
Blüher, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.146 · Cited by 15
Self-citationCegla, J., Cuenco, J., MINNION, J. S., Ghourab, S., Hostomska, K., Tan, T., & Bloom, S. R. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60343-9 · Cited by 6
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Self-citationThe aetiology and molecular landscape of insulin resistance
James, D. E., Stöckli, J., & Birnbaum, M. J. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00390-6 · Cited by 690
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Metadata
- Authors
- Blüher, M.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Blüher, Matthias
- ORCID
- Blüher, Matthias
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-03-04
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7098708
- OpenAlex
- W3009496837
- Cited by
- 1,090
- References
- 123
- Citations by year
- 2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
- FWCI
- 86.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (209933838)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
- MeSH terms
- Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.